244 related articles for article (PubMed ID: 17150306)
1. Expression of glutamate carboxypeptidase II in human brain.
Sácha P; Zámecník J; Barinka C; Hlouchová K; Vícha A; Mlcochová P; Hilgert I; Eckschlager T; Konvalinka J
Neuroscience; 2007 Feb; 144(4):1361-72. PubMed ID: 17150306
[TBL] [Abstract][Full Text] [Related]
2. Deletion of the glutamate carboxypeptidase II gene in mice reveals a second enzyme activity that hydrolyzes N-acetylaspartylglutamate.
Bacich DJ; Ramadan E; O'Keefe DS; Bukhari N; Wegorzewska I; Ojeifo O; Olszewski R; Wrenn CC; Bzdega T; Wroblewska B; Heston WD; Neale JH
J Neurochem; 2002 Oct; 83(1):20-9. PubMed ID: 12358725
[TBL] [Abstract][Full Text] [Related]
3. Biochemical characterization of human glutamate carboxypeptidase III.
Hlouchová K; Barinka C; Klusák V; Sácha P; Mlcochová P; Majer P; Rulísek L; Konvalinka J
J Neurochem; 2007 May; 101(3):682-96. PubMed ID: 17241121
[TBL] [Abstract][Full Text] [Related]
4. Detection and quantitation of glutamate carboxypeptidase II in human blood.
Knedlík T; Navrátil V; Vik V; Pacík D; Šácha P; Konvalinka J
Prostate; 2014 May; 74(7):768-80. PubMed ID: 24647901
[TBL] [Abstract][Full Text] [Related]
5. Identification of the N-glycosylation sites on glutamate carboxypeptidase II necessary for proteolytic activity.
Barinka C; Sácha P; Sklenár J; Man P; Bezouska K; Slusher BS; Konvalinka J
Protein Sci; 2004 Jun; 13(6):1627-35. PubMed ID: 15152093
[TBL] [Abstract][Full Text] [Related]
6. Tissue distribution of glutamate carboxypeptidase II (GCPII) with a focus on the central and peripheral nervous system.
Marmiroli P; Slusher B; Cavaletti G
Curr Med Chem; 2012; 19(9):1277-81. PubMed ID: 22304706
[TBL] [Abstract][Full Text] [Related]
7. Structure-activity relationships of glutamate carboxypeptidase II (GCPII) inhibitors.
Ferraris DV; Shukla K; Tsukamoto T
Curr Med Chem; 2012; 19(9):1282-94. PubMed ID: 22304717
[TBL] [Abstract][Full Text] [Related]
8. Parallel Metabolomics and Lipidomics of a PSMA/GCPII Deficient Mouse Model Reveal Alteration of NAAG Levels and Brain Lipid Composition.
Sedlák F; Kvasnička A; Marešová B; Brumarová R; Dobešová D; Dostálová K; Šrámková K; Pehr M; Šácha P; Friedecký D; Konvalinka J
ACS Chem Neurosci; 2024 Apr; 15(7):1342-1355. PubMed ID: 38377674
[TBL] [Abstract][Full Text] [Related]
9. Deletion of glutamate carboxypeptidase II (GCPII), but not GCPIII, provided long-term benefits in mice with traumatic brain injury.
Ji T; Pang Y; Cheng M; Wang R; Chen X; Zhang C; Liu M; Zhang J; Zhong C
CNS Neurosci Ther; 2023 Dec; 29(12):3786-3801. PubMed ID: 37349952
[TBL] [Abstract][Full Text] [Related]
10. Glutamate carboxypeptidase II does not process amyloid-β peptide.
Sedlák F; Šácha P; Blechová M; Březinová A; Šafařík M; Šebestík J; Konvalinka J
FASEB J; 2013 Jul; 27(7):2626-32. PubMed ID: 23525279
[TBL] [Abstract][Full Text] [Related]
11. The cloning and characterization of a second brain enzyme with NAAG peptidase activity.
Bzdega T; Crowe SL; Ramadan ER; Sciarretta KH; Olszewski RT; Ojeifo OA; Rafalski VA; Wroblewska B; Neale JH
J Neurochem; 2004 May; 89(3):627-35. PubMed ID: 15086519
[TBL] [Abstract][Full Text] [Related]
12. Glutamate carboxypeptidase II is not an amyloid peptide-degrading enzyme.
Alt J; Stathis M; Rojas C; Slusher B
FASEB J; 2013 Jul; 27(7):2620-5. PubMed ID: 23525278
[TBL] [Abstract][Full Text] [Related]
13. Comparative analysis of monoclonal antibodies against prostate-specific membrane antigen (PSMA).
Tykvart J; Navrátil V; Sedlák F; Corey E; Colombatti M; Fracasso G; Koukolík F; Bařinka C; Sácha P; Konvalinka J
Prostate; 2014 Dec; 74(16):1674-90. PubMed ID: 25262926
[TBL] [Abstract][Full Text] [Related]
14. Amino acids at the N- and C-termini of human glutamate carboxypeptidase II are required for enzymatic activity and proper folding.
Barinka C; Mlcochová P; Sácha P; Hilgert I; Majer P; Slusher BS; Horejsí V; Konvalinka J
Eur J Biochem; 2004 Jul; 271(13):2782-90. PubMed ID: 15206943
[TBL] [Abstract][Full Text] [Related]
15. Comparison of human glutamate carboxypeptidases II and III reveals their divergent substrate specificities.
Navrátil M; Tykvart J; Schimer J; Pachl P; Navrátil V; Rokob TA; Hlouchová K; Rulíšek L; Konvalinka J
FEBS J; 2016 Jul; 283(13):2528-45. PubMed ID: 27208881
[TBL] [Abstract][Full Text] [Related]
16. Regulation of glutamate carboxypeptidase II hydrolysis of N-acetylaspartylglutamate (NAAG) in crayfish nervous tissue is mediated by glial glutamate and acetylcholine receptors.
Urazaev AK; Grossfeld RM; Lieberman EM
J Neurochem; 2005 May; 93(3):605-10. PubMed ID: 15836619
[TBL] [Abstract][Full Text] [Related]
17. N-acetylaspartylglutamate (NAAG) and glutamate carboxypeptidase II: An abundant peptide neurotransmitter-enzyme system with multiple clinical applications.
Neale JH; Yamamoto T
Prog Neurobiol; 2020 Jan; 184():101722. PubMed ID: 31730793
[TBL] [Abstract][Full Text] [Related]
18. Still NAAG'ing After All These Years: The Continuing Pursuit of GCPII Inhibitors.
Vornov JJ; Hollinger KR; Jackson PF; Wozniak KM; Farah MH; Majer P; Rais R; Slusher BS
Adv Pharmacol; 2016; 76():215-55. PubMed ID: 27288079
[TBL] [Abstract][Full Text] [Related]
19. Acetylation regulates the stability of glutamate carboxypeptidase II protein in human astrocytes.
Choi JY; Kim JH; Jo SA
Biochem Biophys Res Commun; 2014 Jul; 450(1):372-7. PubMed ID: 24939622
[TBL] [Abstract][Full Text] [Related]
20. Substrate specificity, inhibition and enzymological analysis of recombinant human glutamate carboxypeptidase II.
Barinka C; Rinnová M; Sácha P; Rojas C; Majer P; Slusher BS; Konvalinka J
J Neurochem; 2002 Feb; 80(3):477-87. PubMed ID: 11905994
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
